47 completed, 16 terminated, 5 unknown, 5 withdrawn. 57 Phase 2, 21 Phase 1, 11 Phase 3, 5 Early Phase 1, 2 Not applicable.
Follow Adrucil: new trials by email Literature Review of Adrucil trials Research Report on Adrucil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-08-31 | 2026-06-23 |
| 5-Fluorouracil Response and Optimization STudy (The FROST Trial) 5-Fluorouracil - Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma | Phase 2 | Recruiting | Washington University School of Medicine | 46 | 2026-04-21 | 2026-04-27 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 96 | 2024-04-01 | 2024-03-15 |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil - Endometrial Cancer, Gastric Cancer | Phase 2 | Recruiting | AstraZeneca | 454 | 2022-09-06 | 2026-09-23 |
| FOLFIRINOX + NIS793 in Pancreatic Cancer FOLFIRINOX, Oxaliplatin, Leucovorin - Pancreas Cancer, Metastatic Pancreatic Cancer | Phase 1 | Terminated | Colin D. Weekes, M.D., PhD | 4 | 2022-08-09 | 2025-11-18 |
| NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer Durvalumab, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 2 | Active not recruiting | Australasian Gastro-Intestinal Trials Group | 20 | 2022-05-20 | 2026-05-06 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver | Phase 2 / Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-11-01 | 2022-04-01 | |
| PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC TAK-676, Carboplatin, 5-FU - Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Completed | Presage Biosciences | 15 | 2021-07-26 | 2023-10-06 |
| FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer Digoxin, 5Fluorouracil, Calcium Leucovorin - Pancreas Cancer, Adenocarcinoma of the Pancreas | Phase 2 | Terminated | University of Nebraska | 11 | 2021-02-12 | 2026-10-21 |
| Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Olaparib, 5-FU, Bevacizumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 335 | 2020-08-19 | 2024-10-29 |
| Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Nivolumab, relatlimab, Oxaliplatin - Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | Phase 2 | Unknown | University Hospital, Essen | 21 | 2019-09-26 | 2024-03-12 |
| FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium - Biliary Tract Cancer | Phase 2 | Withdrawn | Samsung Medical Center | 2019-09-06 | 2022-06-15 | |
| Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy 5-FU, Leucovorin, Liposomal Irinotecan - Pancreatic Cancer, Pancreas Cancer | Phase 1 | Completed | Washington University School of Medicine | 20 | 2019-07-11 | 2022-10-05 |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Oxaliplatin, Leucovorin, Irinotecan Hydrochloride - Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2019-06-12 | 2026-01-13 |
| Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC 5-fluorouracil, Calcipotriene - Carcinoma, Squamous Cell | Phase 1 | Recruiting | Melissa Pugliano-Mauro | 30 | 2018-08-03 | 2026-06-01 |
| Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers Oxaliplatin, Capecitabine, Leucovorin - Gastrointestinal Cancer | Early Phase 1 | Terminated | Tannaz Armaghany | 6 | 2018-06-22 | 2020-10-12 |
Showing 20 of 85. Sign in to see all of them.
Pancreatic Neoplasms (17) · Colorectal Neoplasms (12) · Breast Neoplasms (10) · Colonic Neoplasms (9) · Stomach Neoplasms (9) · Esophageal Neoplasms (6) · Rectal Neoplasms (6) · Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Head and Neck Neoplasms (4) · Carcinoma, Squamous Cell (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Adenoma, Islet Cell (2)
M.D. Anderson Cancer Center (22) · National Cancer Institute (NCI) (4) · City of Hope Medical Center (3) · ECOG-ACRIN Cancer Research Group (3) · Sumitomo Pharma America, Inc. (3) · Washington University School of Medicine (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Genentech, Inc. (2) · Merck Sharp & Dohme LLC (2) · Roswell Park Cancer Institute (2) · Spanish Breast Cancer Research Group (2) · Stanford University (2) · UNC Lineberger Comprehensive Cancer Center (2) · University of California, San Francisco (2) · AIDS Malignancy Consortium (1)
United States (72) · Spain (9) · Canada (6) · France (6) · Germany (6) · Italy (6) · Belgium (5) · Australia (4) · South Korea (4) · Japan (3) · United Kingdom (3) · China (2) · Hungary (2) · Poland (2) · Russia (2)
Jaffer Ajani, MD (3) · Apostolia M. Tsimberidou, MD, PhD (2) · Daniel T Chang (2) · Joseph A. Sparano, MD (2) · Lisa Licitra, MD (2) · Marco Benazzo, MD (2) · Piero Nicolai, MD (2) · Vincent Chung (2) · Al B. Benson, MD (1) · Al Benson (1) · Albert Koong (1) · Andrea Sponghini, MD (1) · Anthony Shields (1)
PMID 40207789, PMID 21121833, PMID 21422418, PMID 23293700, PMID 23733779, PMID 23756764, PMID 23975663, PMID 24669015, PMID 25547133, PMID 26908161, PMID 27937092, PMID 27978579, PMID 29218623, PMID 29235564, PMID 29506988, PMID 29879283, PMID 30817250, PMID 32205017, PMID 32939319, PMID 33099678, PMID 34779646, PMID 36183444, PMID 38749110, PMID 38842838, PMID 40340830, PMID 41397917, PMID 42859303
P30CA016672 (3), U10CA023318 (3), U10CA021115 (2), U10CA180888 (2), 2005 (1), 2014 (1), 2016 (1), 2019 (1), 2023 (1), K23CA121994 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA016056 (1), P30CA022453 (1)